![Figure 2. Induction of myocardin transcription and migration in hMSCs by endothelial cells. (A) Quantitative real-time PCR was performed to assess the induction of myocardin in hMSCs by various conditions after 2 days (hMSCs alone, hMSCs cultured with MS1 endothelial cells with contact, hMSCs cultured with MS1 without contact by transwell culture, and hMSCs stimulated with TGFβ1 [10 ng/mL]). Values expressed as fold increase above hMSC-alone levels and normalized by GAPDH. Representative data of 3 separate experiments. (B) Transwell migration assay was performed to assess endothelial cell–induced hMSC migration. Imatinib mesylate at 0.2 μM, 2 μM, and 10 μM was added to test for inhibition of hMSC migration. #P < .001 (medium vs HUVECs); *P < .001 (2 μM imatinib mesylate vs HUVECs); **P < .001 (10 μM imatinib mesylate vs HUVECs).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/111/9/10.1182_blood-2007-10-118273/4/zh80080818120002.jpeg?Expires=1723328597&Signature=cx7tkfZrQFbaLAzjprgVjJ44NFdcZaNsaV5770sFvbTV1sYIqoVlUAy~i5yBaJrwdfYkjwI0mxksieEu5Lj4hNtKM5u8UP5kE5W8sWSv5EX5Q9vZ6tTUfx7tiTko37gyAYaMuh-KI1gTCHGG1~woTMEomVOGGRBeMiEoowa7jjVzIHD3dKlNJ0l5imzxLYfphr2MEEICBRyN9G313aKzUbH8D8Ssvor8wlgxQv3zR6yDEd74C5y4sbYyqwnDnKnCLD6nFseBc7bFtN5FiRzY0K8A5BCFMdeWNjJlrQBRfkvSUfBkv9C6ZRHKnLngQ9ZEFBWtvITban4GEk4uJn3nRg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Induction of myocardin transcription and migration in hMSCs by endothelial cells. (A) Quantitative real-time PCR was performed to assess the induction of myocardin in hMSCs by various conditions after 2 days (hMSCs alone, hMSCs cultured with MS1 endothelial cells with contact, hMSCs cultured with MS1 without contact by transwell culture, and hMSCs stimulated with TGFβ1 [10 ng/mL]). Values expressed as fold increase above hMSC-alone levels and normalized by GAPDH. Representative data of 3 separate experiments. (B) Transwell migration assay was performed to assess endothelial cell–induced hMSC migration. Imatinib mesylate at 0.2 μM, 2 μM, and 10 μM was added to test for inhibition of hMSC migration. #P < .001 (medium vs HUVECs); *P < .001 (2 μM imatinib mesylate vs HUVECs); **P < .001 (10 μM imatinib mesylate vs HUVECs).
